がんコンパニオン診断薬の世界市場レポート 2025年

がんコンパニオン診断薬の市場規模は今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）13.0％で62億1,000万米ドルに成長します。予測期間の成長は、個別化医療の重要性の高まり、診断検査の増加、個別化がん治療への注目の高まり、ヘルスケア支出の増加、がん罹患率と認知度の上昇に起因すると考えられます。予測期間における主な動向としては、診断技術の進歩、次世代シーケンシング（NGS）、人工知能（AI）の統合、リキッドバイオプシー技術、ポイントオブケア型コンパニオン診断機器の開発、革新的な検査技術などが挙げられます。

がんの有病率の増加は、今後のがんコンパニオン診断薬市場の成長を牽引すると予想されます。がんは、制御不能に広がる異常な細胞増殖を特徴とする複雑な疾患群です。がん患者の増加は、ライフスタイルの変化、環境の影響、肥満の流行、タバコの使用、遺伝的素因などの要因に起因しています。がんコンパニオン診断薬は精密医療において重要な役割を果たし、個別化された治療法の選択を可能にし、治療効果を改善し、副作用を軽減し、臨床試験への参加を容易にし、治療モニタリングを強化することによって、がん治療を変革します。例えば、米国の政府機関である国立がん研究所は、2024年5月に、2022年には年間約2,000万人のがん患者が新たに発生し、970万人ががんに関連して死亡したと報告しました。2040年までには、新たながん罹患者数は2,990万人に増加し、がん関連死は年間1,530万人になると予測されています。その結果、がん罹患率の増加ががんコンパニオン診断薬市場の成長を牽引しています。

がんコンパニオン診断薬市場の主要企業は、競争力を維持するために革新的な製品、特に体外診断用医薬品の開発に力を注いでいます。体外診断検査は、体外の患者から採取したサンプルを用いて、管理された実験室環境で実施され、腫瘍の生物学に関する重要な洞察を提供し、治療の意思決定の指針となります。例えば、著名なバイオテクノロジー企業であるイルミナ社は、2022年5月にTruSight Oncology（TSO）Comprehensive（EU）検査の汎がんコンパニオン診断（CDx）適応を導入しました。この診断アッセイは、複数の腫瘍遺伝子とバイオマーカーを評価することにより、包括的な腫瘍プロファイルを提供し、医療提供者に様々な固形悪性新生物患者の標的療法を調整する力を与えます。腫瘍の変異負荷（TMB）やマイクロサテライト不安定性（MSI）の状態などの重要なパラメータを評価することにより、この検査は治療の精度と有効性を高めます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界がんコンパニオン診断薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のがんコンパニオン診断薬市場：成長率分析
• 世界のがんコンパニオン診断薬市場の実績：規模と成長, 2019-2024
• 世界のがんコンパニオン診断薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界がんコンパニオン診断薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがんコンパニオン診断薬市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 機器
• 消耗品
• ソフトウェア
• 世界のがんコンパニオン診断薬市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 黒色腫
• 乳がん
• 大腸がん
• 白血病
• 前立腺がん
• その他の病気の種類
• 世界のがんコンパニオン診断薬市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫組織化学（IHC）
• インサイチューハイブリダイゼーション（ISH）または蛍光インサイチューハイブリダイゼーション（FISH）
• ポリメラーゼ連鎖反応（PCR）
• 次世代シーケンシング（NGS）
• その他のテクノロジー
• 世界のがんコンパニオン診断薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 病理学または診断研究室
• 学術医療センター
• その他のエンドユーザー
• 世界のがんコンパニオン診断薬市場、楽器のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ポリメラーゼ連鎖反応（PCR）装置
• 次世代シーケンシング（NGS）システム
• 免疫組織化学（IHC）機器
• 蛍光in situハイブリダイゼーション（FISH）装置
• マイクロアレイプラットフォーム
• 世界のがんコンパニオン診断薬市場消耗品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 試薬およびキット（DNAまたはRNA抽出キット、PCR試薬）
• 生検針
• スライドとチップのテスト
• 管理および校正サンプル
• 世界のがんコンパニオン診断薬市場ソフトウェアの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• データ分析ソフトウェア
• バイオインフォマティクスソフトウェア（遺伝子発現解析用）
• コンパニオン診断意思決定支援ソフトウェア
• 臨床ワークフロー管理ソフトウェア

第7章 地域別・国別分析

• 世界のがんコンパニオン診断薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のがんコンパニオン診断薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がんコンパニオン診断薬市場：競合情勢
• がんコンパニオン診断薬市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Diagnostic Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Laboratory Corporation of America Holdings（LabCorp）
• Quest Diagnostics Incorporated
• Eurofins Scientific SE
• Agilent Technologies Inc.
• Illumina Inc.
• PerkinElmer Inc.
• bioMerieux SA
• Sysmex Corporation
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• Exact Sciences Corporation
• BGI Genomics Co. Ltd.
• Natera Inc.
• Myriad Genetics Inc.
• ARUP Laboratories

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がんコンパニオン診断薬市場2029：新たな機会を提供する国
• がんコンパニオン診断薬市場2029：新たな機会を提供するセグメント
• がんコンパニオン診断薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Oncology companion diagnostics are medical tests designed to identify specific biomarkers, indicating which patients are most likely to respond favorably to a particular cancer treatment. These diagnostics play a crucial role in the development and application of targeted therapies, ensuring that treatments are customized to match the unique characteristics of a patient's tumor. By providing insights into the molecular and genetic profile of cancer, companion diagnostics enable more personalized and efficient treatment strategies, leading to improved outcomes and reduced adverse effects.

The primary products within the oncology companion diagnostics market include instruments, consumables, and software. Instruments encompass a diverse array of tools and devices utilized for various purposes across different fields. These diagnostics cater to a range of disease types such as melanoma, breast cancer, colorectal cancer, leukemia, prostate cancer, among others. They leverage various technologies including immunohistochemistry (IHC), in situ hybridization (ISH) or fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. End users of oncology companion diagnostics include hospitals, pathology or diagnostic laboratories, academic medical centers, and others.

The oncology companion diagnostics market research report is one of a series of new reports from The Business Research Company that provides oncology companion diagnostics market statistics, including oncology companion diagnostics industry global market size, regional shares, competitors with an oncology companion diagnostics market share, detailed oncology companion diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the oncology companion diagnostics industry. This oncology companion diagnostics research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oncology companion diagnostics market size has grown rapidly in recent years. It will grow from $3.35 billion in 2024 to $3.8 billion in 2025 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to increasing cases of adverse drug reactions, increasing demand for comprehensive genomic testing, the increasing global incidence of cancer, the growing need for targeted therapy, and the growing number of clinical trials.

The oncology companion diagnostics market size is expected to see rapid growth in the next few years. It will grow to $6.21 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to the rising importance of personalized medicine, increasing diagnostic tests, increasing focus on personalized cancer therapy, increasing healthcare expenditure, and increasing cancer incidence and awareness. Major trends in the forecast period include advancements in diagnostic technologies, next-generation sequencing (NGS), integration of artificial intelligence (AI), liquid biopsy technologies, the development of point-of-care companion diagnostic devices, and innovative testing technologies.

The increasing prevalence of cancer is expected to drive the growth of the oncology companion diagnostics market in the future. Cancer is a complex group of diseases characterized by abnormal cell growth that spreads uncontrollably. The rise in cancer cases can be attributed to factors such as lifestyle changes, environmental influences, the obesity epidemic, tobacco use, and genetic predispositions. Oncology companion diagnostics play a critical role in precision medicine, transforming cancer care by enabling personalized treatment selection, improving treatment effectiveness, reducing side effects, facilitating clinical trial participation, and enhancing treatment monitoring. For example, the National Cancer Institute, a US-based government agency, reported in May 2024 that approximately 20 million new cancer cases and 9.7 million cancer-related deaths occurred annually in 2022. By 2040, predictions suggest that the number of new cancer cases will rise to 29.9 million, with 15.3 million cancer-related deaths annually. As a result, the increasing cancer incidence is driving the growth of the oncology companion diagnostics market.

Leading companies in the oncology companion diagnostics market are concentrating their efforts on developing innovative products, particularly in vitro diagnostic tests, to maintain their competitive edge. In vitro diagnostic tests, conducted on samples obtained from patients outside of the body in controlled laboratory environments, provide critical insights into tumor biology and guide treatment decision-making. For example, Illumina Inc., a prominent biotechnology company, introduced a pan-cancer companion diagnostic (CDx) indication for its TruSight Oncology (TSO) Comprehensive (EU) test in May 2022. This diagnostic assay offers a comprehensive tumor profile by evaluating multiple tumor genes and biomarkers, empowering healthcare providers to tailor targeted therapy for patients with various solid malignant neoplasms. By assessing essential parameters such as tumor mutational burden (TMB) and microsatellite instability (MSI) status, this test enhances treatment precision and effectiveness.

In January 2024, Agilent Technologies Inc., a US-based diagnostics company, entered into a partnership with Incyte Corporation for an undisclosed amount. This collaboration aims to strengthen Agilent's companion diagnostics portfolio and support Incyte's hematology and oncology treatments through advanced, precision diagnostics. Incyte Corporation, a US-based pharmaceutical company, specializes in the development and commercialization of oncology medications.

Major companies operating in the oncology companion diagnostics market are F. Hoffmann-La Roche AG, Bayer Diagnostic, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., bioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, BGI Genomics Co. Ltd., Natera Inc., Myriad Genetics Inc., ARUP Laboratories, NeoGenomics Laboratories Inc., Guardant Health, Ambry Genetics Corporation, Biocartis SA, CENTOGENE N.V., Invivoscribe Inc., Pillar Biosciences Inc.

North America was the largest region in the oncology companion diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oncology companion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncology companion diagnostics market consists of revenues earned by entities by providing services such as biomarker testing, patient stratification, monitoring treatment response, predicting drug resistance, clinical trial enrollment, comprehensive genomic testing, therapy resistance testing, hereditary cancer testing, and risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology companion diagnostics market also includes sales of polymerase chain reaction instruments, immunohistochemistry (IHC) staining kits, companion diagnostic test kits, liquid biopsy platforms, gene expression profiling kits, mass spectrometry systems, flow cytometry analyzers, tissue microarray instruments, and electrochemical biosensors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Companion Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology companion diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology companion diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology companion diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Instrument; Consumables; Software
• 2) By Disease Type: Melanoma; Breast Cancer; Colorectal Cancer; Leukemia; Prostate Cancer; Other Disease Types
• 3) By Technology: Immunohistochemistry (IHC); In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH); Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
• 4) By End User: Hospital; Pathology Or Diagnostic Laboratory; Academic Medical Center; Other End-Users
• Subsegments:
• 1) By Instrument: Polymerase Chain Reaction (Pcr) Instruments; Next-Generation Sequencing (Ngs) Systems; Immunohistochemistry (Ihc) Instruments; Fluorescence In Situ Hybridization (Fish) Instruments; Microarray Platforms
• 2) By Consumables: Reagents And Kits (Dna Or Rna Extraction Kits, Pcr Reagents); Biopsy Needles; Testing Slides And Chips; Control And Calibration Samples
• 3) By Software: Data Analysis Software; Bioinformatics Software ( For Gene Expression Analysis); Companion Diagnostic Decision Support Software; Clinical Workflow Management Software
• Companies Mentioned: F. Hoffmann-La Roche AG; Bayer Diagnostic; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Companion Diagnostics Market Characteristics

3. Oncology Companion Diagnostics Market Trends And Strategies

4. Oncology Companion Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Oncology Companion Diagnostics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Oncology Companion Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Oncology Companion Diagnostics Market Growth Rate Analysis
• 5.4. Global Oncology Companion Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Oncology Companion Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Oncology Companion Diagnostics Total Addressable Market (TAM)

6. Oncology Companion Diagnostics Market Segmentation

• 6.1. Global Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Instrument
• Consumables
• Software
• 6.2. Global Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Melanoma
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Prostate Cancer
• Other Disease Types
• 6.3. Global Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunohistochemistry (IHC)
• In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH)
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Other Technologies
• 6.4. Global Oncology Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Pathology Or Diagnostic Laboratory
• Academic Medical Center
• Other End-Users
• 6.5. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Instrument, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polymerase Chain Reaction (PCR) Instruments
• Next-Generation Sequencing (NGS) Systems
• Immunohistochemistry (IHC) Instruments
• Fluorescence In Situ Hybridization (FISH) Instruments
• Microarray Platforms
• 6.6. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Consumables, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Reagents And Kits (DNA Or RNA Extraction Kits, PCR Reagents)
• Biopsy Needles
• Testing Slides And Chips
• Control And Calibration Samples
• 6.7. Global Oncology Companion Diagnostics Market, Sub-Segmentation Of Software, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Data Analysis Software
• Bioinformatics Software (For Gene Expression Analysis)
• Companion Diagnostic Decision Support Software
• Clinical Workflow Management Software

7. Oncology Companion Diagnostics Market Regional And Country Analysis

• 7.1. Global Oncology Companion Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Oncology Companion Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Companion Diagnostics Market

• 8.1. Asia-Pacific Oncology Companion Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Companion Diagnostics Market

• 9.1. China Oncology Companion Diagnostics Market Overview
• 9.2. China Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Companion Diagnostics Market

• 10.1. India Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Companion Diagnostics Market

• 11.1. Japan Oncology Companion Diagnostics Market Overview
• 11.2. Japan Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Companion Diagnostics Market

• 12.1. Australia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Companion Diagnostics Market

• 13.1. Indonesia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Companion Diagnostics Market

• 14.1. South Korea Oncology Companion Diagnostics Market Overview
• 14.2. South Korea Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Companion Diagnostics Market

• 15.1. Western Europe Oncology Companion Diagnostics Market Overview
• 15.2. Western Europe Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Companion Diagnostics Market

• 16.1. UK Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Companion Diagnostics Market

• 17.1. Germany Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Companion Diagnostics Market

• 18.1. France Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Companion Diagnostics Market

• 19.1. Italy Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Companion Diagnostics Market

• 20.1. Spain Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Companion Diagnostics Market

• 21.1. Eastern Europe Oncology Companion Diagnostics Market Overview
• 21.2. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Companion Diagnostics Market

• 22.1. Russia Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Companion Diagnostics Market

• 23.1. North America Oncology Companion Diagnostics Market Overview
• 23.2. North America Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Companion Diagnostics Market

• 24.1. USA Oncology Companion Diagnostics Market Overview
• 24.2. USA Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Companion Diagnostics Market

• 25.1. Canada Oncology Companion Diagnostics Market Overview
• 25.2. Canada Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Companion Diagnostics Market

• 26.1. South America Oncology Companion Diagnostics Market Overview
• 26.2. South America Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Companion Diagnostics Market

• 27.1. Brazil Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Companion Diagnostics Market

• 28.1. Middle East Oncology Companion Diagnostics Market Overview
• 28.2. Middle East Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Companion Diagnostics Market

• 29.1. Africa Oncology Companion Diagnostics Market Overview
• 29.2. Africa Oncology Companion Diagnostics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Oncology Companion Diagnostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Oncology Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Companion Diagnostics Market Competitive Landscape And Company Profiles

• 30.1. Oncology Companion Diagnostics Market Competitive Landscape
• 30.2. Oncology Companion Diagnostics Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer Diagnostic Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Companion Diagnostics Market Other Major And Innovative Companies

• 31.1. Laboratory Corporation of America Holdings (LabCorp)
• 31.2. Quest Diagnostics Incorporated
• 31.3. Eurofins Scientific SE
• 31.4. Agilent Technologies Inc.
• 31.5. Illumina Inc.
• 31.6. PerkinElmer Inc.
• 31.7. bioMerieux SA
• 31.8. Sysmex Corporation
• 31.9. Bio-Rad Laboratories Inc.
• 31.10. QIAGEN N.V.
• 31.11. Exact Sciences Corporation
• 31.12. BGI Genomics Co. Ltd.
• 31.13. Natera Inc.
• 31.14. Myriad Genetics Inc.
• 31.15. ARUP Laboratories

32. Global Oncology Companion Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Companion Diagnostics Market

34. Recent Developments In The Oncology Companion Diagnostics Market

35. Oncology Companion Diagnostics Market High Potential Countries, Segments and Strategies

• 35.1 Oncology Companion Diagnostics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Oncology Companion Diagnostics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Oncology Companion Diagnostics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer